Characterizing and controlling CRISPR repair outcomes in nondividing human cells

Gokul N. Ramadoss(Gladstone Institutes), Samali J. Namaganda(Gladstone Institutes), Manasi M. Kumar(Gladstone Institutes), Jennifer Hamilton(Innovative Genomics Institute), Rohit Sharma(Innovative Genomics Institute), Karena G. Chow(Gladstone Institutes), Luke A. Workley(Gladstone Institutes), Bria L Macklin(Gladstone Institutes), Mengyuan Sun(Gladstone Institutes), Alvin Ha(Gladstone Institutes), Jiacheng Liu(National Human Genome Research Institute), Christof Fellmann(Gladstone Institutes), Hannah L. Watry(Gladstone Institutes), Philip H. Dierks(Gladstone Institutes), Rudra S. Bose(University of California, San Francisco), Julianne Jin(University of California, San Francisco), Barbara S. Perez(Innovative Genomics Institute), Cindy R. Sandoval Espinoza(Innovative Genomics Institute), Madeline Matia(Gladstone Institutes), Serena Huei-An Lu(Gladstone Institutes), Luke M. Judge(Gladstone Institutes), Brian R. Shy(Gladstone Institutes), André Nussenzweig(National Human Genome Research Institute), Britt Adamson(Princeton University), Niren Murthy(Innovative Genomics Institute), Jennifer A. Doudna(QB3), Martin Kampmann(University of California, San Francisco), Bruce R. Conklin(Gladstone Institutes)
Nature Communications
November 17, 2025
Cited by 7Open Access
Full Text

Abstract

Genome editing is poised to revolutionize treatment of genetic diseases, but poor understanding and control of DNA repair outcomes hinders its therapeutic potential. DNA repair is especially understudied in nondividing cells like neurons, limiting the efficiency and precision of genome editing in many clinically relevant tissues. Here, we address this barrier by using induced pluripotent stem cells (iPSCs) and iPSC-derived neurons to examine how postmitotic human neurons repair Cas9-induced DNA damage. CRISPR editing outcomes differ dramatically in neurons compared to genetically identical dividing cells: neurons take longer to fully resolve this damage, and upregulate non-canonical DNA repair factors in the process. Manipulating this response with chemical or genetic perturbations allows us to direct DNA repair toward desired editing outcomes in nondividing human neurons, cardiomyocytes, and primary T cells. By studying DNA repair in clinically relevant cells, we reveal unforeseen challenges and opportunities for precise therapeutic editing.


Related Papers